13 Results for "

HGFs cells

" in MedChemExpress (MCE) Product Catalog:
Products (13)

13 Results for "HGFs cells" in MCE Product Catalog:

3
3 Cited Publications
Cat. No.: HY-18696
CAS No.: 1173699-31-4
Research Areas:  

Cancer

AMG-337 is a potent, orally active, selective MET kinase inhibitor with IC50 values of 1, 1, 4.7, 5, 21.5, 1077 and >4000 nM of WT MET, H1094R MET, M1250T MET, HGF-stimulated pMET (PC3 cells) MET, V1092I MET, Y1230H MET, and D1228H MET, respectively. AMG 337 inhibits the phosphorylation of MET and downstream effectors in MET-amplified cancer cell lines, resulting in an inhibition of MET-dependent cell proliferation and induction of apoptosis .
loading...
    loading...
Cat. No.: HY-P99391
CAS No.: 1781223-80-0
Synonyms: ABT-700; ABBV-400 Antibody
Target:  

c-Met/HGFR Apoptosis

Research Areas:  

Cancer

Telisotuzumab (ABT-700) is a bivalent humanized IgG1 anti-c-Met monoclonal antibody. Telisotuzumab binds cellular c-Met and disrupts its productive dimerization and activation induced by HGF or by the high density of c-Met on the cell surface independent of ligand. Telisotuzumab induces apoptosis. The Fc hinge region of Telisotuzumab has been engineered to enhance its rigidity by introducing a new disulfide bond (K222C) and shortening the hinge length (T223del, T225del). Telisotuzumab can be used for the study of cancers harboring amplified MET, such as gastric and lung cancers .
loading...
    loading...
Cat. No.: HY-P99196
CAS No.: 1174900-84-5

Target:  

c-Met/HGFR

Research Areas:  

Cancer

Ficlatuzumab is a monoclonal antibody (McAb) targeting human hepatocyte growth factor (HGF). Ficlatuzumab blocks the activation of the HGF/c-Met signaling pathway, and inhibits c-Met receptor-mediated cancer cell proliferation, migration, and invasion .
loading...
    loading...
Cat. No.: HY-106961
CAS No.: 176391-41-6
Purity:  99.06%
Synonyms: ONO-AP 500-02
Research Areas:  

Cardiovascular Disease

ONO 1301 (ONO-AP 500-02), a prostaglandin (PG) I2 mimetic, is an orally active, long-acting prostacyclin agonist with thromboxane-synthase inhibitory activity. ONO 1301 promotes production of hepatocyte growth factor (HGF) from various cell types and ameliorates ischemia-induced left ventricle dysfunction in the mouse, rat and pig .
loading...
    loading...
Cat. No.: HY-106961A
CAS No.: 153814-74-5
Synonyms: (Z)-ONO-AP 500-02
Research Areas:  

Cardiovascular Disease

(Z)-ONO 1301 is the isomer of ONO 1301 (HY-106961), and can be used as an experimental control. ONO 1301 (ONO-AP 500-02), a prostaglandin (PG) I2 mimetic, is an orally active, long-acting prostacyclin agonist with thromboxane-synthase inhibitory activity. ONO 1301 promotes production of hepatocyte growth factor (HGF) from various cell types and ameliorates ischemia-induced left ventricle dysfunction in the mouse, rat and pig .
loading...
    loading...
Cat. No.: HY-P991660

Target:  

c-Met/HGFR

Research Areas:  

Cancer

ARGX-111 is an anti-MET antibody. ARGX-111 blocks HGF-dependent and -independent signaling, downregulating MET expression on the tumor cell surface. ARGX-111 depletes MET-expressing circulating tumor cells through enhanced antibody-dependent cell-mediated cytotoxicity (ADCC), thereby inhibiting tumor metastasis. ARGX-111 depletes circulating tumor cells and inhibits bone and lung metastasis in an orthotopic mouse model of metastatic breast cancer. ARGX-111 is promising for research in breast cancer and other cancers .
loading...
    loading...
Cat. No.: HY-P991589
Synonyms: NOV-1105

Target:  

c-Met/HGFR

Research Areas:  

Cancer

SFN68 is a humanized IgG1 neutralizing monoclonal antibody targeting HGF. SFN68 significantly inhibits HGF/c-Met interaction, c-Met activation, and, cell scattering and proliferation mediated by HGF. SFN68 can be used for cancers research .
loading...
    loading...
Cat. No.: HY-P991565

Target:  

c-Met/HGFR

Research Areas:  

Cancer

CE-355621 is a humanized anti-c-Met IgG1 monoclonal antibody. CE-355621 can effectively bind with human c-Met (KD = 200 pM, IC50 = 466 pM) in A549 cells and cyno c-Met (KD = 610 pM) in cynomolgus kidney cells. CE-355621 inhibits the c-Met signaling pathway by blocking HGF binding. CE-355621 significantly inhibits the growth of tumors dependent on the c-Met/HGF pathway. CE-355621 can be used for research on cancer such as glioblastoma and gastric cancer .
loading...
    loading...
Cat. No.: HY-10338A
CAS No.: 1226999-07-0
Target:  

c-Met/HGFR VEGFR

Research Areas:  

Cancer

Foretinib phosphate is an orally bioavailable small molecule with potential anti-tumor activity. Foretinib phosphate can selectively inhibit hepatocyte growth factor (HGF) receptor c-MET and vascular endothelial growth factor receptor 2 (VEGFR2), thereby potentially inhibiting tumor angiogenesis, tumor cell proliferation and metastasis. Foretinib phosphate shows different anti-cancer activity from cabozantinib in lung cancer cells and has stronger inhibitory effects on targets such as MEK1/2, FER and AURKB .
loading...
    loading...
Cat. No.: HY-P99391A
CAS No.: 1781223-80-0
Synonyms: ABT-700 (powder)

Target:  

c-Met/HGFR Apoptosis

Research Areas:  

Cancer

Telisotuzumab (ABT-700) (powder) is a bivalent humanized IgG1 anti-c-Met monoclonal antibody. Telisotuzumab (powder) binds cellular c-Met and disrupts its productive dimerization and activation induced by HGF or by the high density of c-Met on the cell surface independent of ligand. Telisotuzumab (powder) induces apoptosis. Telisotuzumab (powder) can be used for the study of cancers harboring amplified MET, such as gastric and lung cancers .
loading...
    loading...
Cat. No.: HY-174670
Target:  

mRNA

Research Areas:  

Cancer

Human HGF mRNA encodes the human hepatocyte growth factor (HGF) protein, a protein that binds to the hepatocyte growth factor receptor to regulate cell growth, cell motility and morphogenesis in numerous cell and tissue types. It also plays a role in angiogenesis, tumorogenesis, and tissue regeneration.
loading...
    loading...
Cat. No.: HY-P992396

Target:  

c-Met/HGFR

Research Areas:  

Cancer

KTN0073 is a high-affinity MET receptor tyrosine kinase inhibitor. KTN0073 can be used in studies related to non-small cell lung cancer and human cancers driven by HGF, MET amplification, or exon 14 mutation. KTN0073 binds to the Sema/PSI domain to block the HGF-MET interaction, and induces ubiquitination and degradation of oncogenic MET receptors via an HGF-independent pathway, thereby inhibiting MET-dependent signal transduction. KTN0073 exhibits significant antitumor activity in vivo, and its tumor suppressive activity is superior to that of the IgG1 subtype when grafted to the IgG2 constant region .
loading...
    loading...
Cat. No.: HY-106961R
CAS No.: 176391-41-6
Synonyms: ONO-AP 500-02 (Standard)
ONO 1301 (Standard) (ONO-AP 500-02 (Standard)) is the analytical standard of ONO 1301 (HY-106961). This product is intended for research and analytical applications. ONO 1301 (ONO-AP 500-02), a prostaglandin (PG) I2 mimetic, is an orally active, long-acting prostacyclin agonist with thromboxane-synthase inhibitory activity. ONO 1301 promotes production of hepatocyte growth factor (HGF) from various cell types and ameliorates ischemia-induced left ventricle dysfunction in the mouse, rat and pig .
loading...
    loading...
  • 1